NOD2 and graft versus host disease: Presence of any NOD2 SNPs or the ATG16L1 variants in either the recipient or the donor increased the risk of GvHD and subsequent treatment related mortality, and this effect was further increased if variants were present in both, donor and recipient (Figure 1).